S-phase kinase-associated protein 2 (SKP2) gene is a tumor suppressor gene, and is involved in the ubiquitinmediated degradation of P27 kip1 . SKP2 and P27 kip1 affect the proceeding and prognosis of leukemia through regulating the proliferation, apoptosis and differentiation of leukemia cells. In this study, we explored the mechanism of reversing of HL-60/A drug resistance through SKP2 down-regulation. HL-60/A cells were nucleofected by Amaxa Nucleofector System with SKP2 siRNA. The gene and protein expression levels of Skp2, P27 kip1 , and multi-drug resistance associated protein (MRP) were determined by reverse transcription-polymerase chain reaction and western blot analysis, respectively. The cell cycle was analyzed by flow cytometry. The 50% inhibitory concentration value was calculated using cytotoxic analysis according to the death rate of these two kinds of cells under different concentrations of chemotherapeutics to compare the sensitivity of the cells. HL-60/A cells showed multi-drug resistance phenotype characteristic by cross-resistance to adriamycin, daunorubicin, and arabinosylcytosine, due to the expression of MRP. We found that the expression of SKP2 was higher in HL-60/A cells than in HL-60 cells, but the expression of P27 kip1 was lower. The expression of SKP2 in HL-60/A cells nucleofected by SKP2 siRNA was down-regulated whereas the protein level of P27 kip1 was up-regulated. Compared with the MRP expression level in the control group (nucleofected by control siRNA), the mRNA and protein expression levels of MRP in HL-60/A cells nucleofected by SKP2 siRNA were lower, and the latter cells were more sensitive to adriamycin, daunorubicin, and arabinosylcytosine. Down-regulating the SKP2 expression and arresting cells in the G 0 /G 1 phase improve drug sensitivity of leukemia cells with down-regulated MRP expression.
Introduction
Acute myeloid leukemia (AML) is a malignant disease in hematology, which shows frequent recurrence and a poor outcome despite combined chemotherapy because of the multi-drug resistance of leukemia cells [1, 2] . Therefore, reversion multi-drug resistance of leukemic cells is important to effectively cure AML patients. The cyclin-dependent kinase inhibitor P27 kip1 is a key regulator of the cell cycle in mammalian cells, which negatively regulates cell cycle progression by directly inhibiting cyclin/Cdk2 complexes [3, 4] . S-phase kinase-associated protein 2 (SKP2) is involved in the ubiquitin-mediated degradation of P27 kip1 in various cancers including AML [5] . SKP2 and P27 kip1 affect the proceeding and prognosis of leukemia through regulating the proliferation, apoptosis, and differentiation of leukemia cells [6 -10] , but whether they can affect the multidrug resistance is still unknown.
RNA interfering (RNAi) involves sequence-specific post-transcription gene silencing by short small interfering RNA (siRNA), which is thought to be a powerful approach for studying gene function and gene therapy. Using the HL-60/A cells as a model of multi-drug resistance leukemia cells that were resistant to adriamycin, daunorubicin, and arabinosylcytosine, we found that the expression of SKP2 or MRP in HL-60/A cells was higher than that in HL-60 cells, but the expression of P27 kip1 was lower. Moreover, we designed and synthesized a pair of siRNA based on SKP2 sequence, which had very good effect. The expression of P27 kip1 in HL-60/A cells nucleofected with siRNA was rapidly increased, which induced G 0 /G 1 phase arresting of the cells. Also, the cells were more sensitive to chemotherapeutics with down-regulated MRP expression.
Materials and Methods
Cell lines and culture conditions HL-60 cells were provided by Department of Pharmaceutical Science, Sun Yat-Sen University (Guangzhou, China), maintained in RPMI 1640 medium containing 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin at 378C in a humidified incubator containing 5% CO 2 (Gibco, Gaithersburg, USA). HL-60/A was constructed using a stepwise increase in concentration gradient of adriamycin. 
SKP2 siRNA and primer
The design and synthesis of SKP2 siRNA were completed by Amaxa (Walkersville, USA). The nucleotide sequences of sense and antisense SKP2 siRNA were: 5 0 -CCUAUCGAACUCAGUUAUATT-3 0 and 5 0 -UAUAACUGAGUUCGAUAGGTC-3 0 . Cy3-labeled negative control siRNA was provided by Amaxa, which did not match any genes of known function in GenBank.
The primers of SKP2, P27 kip1 , MRP, and b-actin were designed by the primer premier 5.0 software and listed in the Table 1 .
Cell transfection
One nucleofection sample contained 2 Â 10 6 cells, 10 ml of 20 mM siRNA and 100 ml Nucleofector Solution V (Amaxa). The supplemented Cell Line Nucleofector Solution V was pre-warmed to room temperature. The 6-well plates filled with culture medium containing supplements and serum were pre-incubated in a humidified 5% CO 2 incubator at 378C. The cells were resuspended in Cell Line Nucleofector Solution V to a final concentration of 2 Â 10 6 cells/100 ml nucleofection. The transfection program was started by mixing the nucleofection sample with 10 ml siRNA and then transferred to an Amaxa certified cuvette. The sample was transferred to a prepared 6-well plates after the program was finished. Cells were incubated in a humidified incubator at 378C with 5% CO 2 .
Reverse transcription-polymerase chain reaction Total RNA was isolated from each group cells using Trizol regent (Invitrogen, Carlsbad, USA) according to the manufacturer's instruction. Total cellular RNA was used for reverse transcription (RT) of cDNA by a standardized technique (MBI Fermentas, Hanover, USA). Obtained cDNA was amplified using specific primers. After pre-denaturation at 958C for 30 s, polymerase chain reaction (PCR) was carried out for 30 cycles: 30 s denaturation at 948C; followed by annealing for 30 s at 55.58C (MRP) or for 30 s at 548C (SKP2, P27 kip1 and b-actin) and finally extended for 1 min at 728C. The PCR products were visualized on 2% agarose gels (BioWest, Madrid, Spain) after staining with colloidal gold. Images of colloidal gold-stained gels were captured by a digital camera. kip1 mAb (R&D System, Minneapolis, USA), MRP mAb (Chemicon, Rosemont, USA), and GAPDH mAb (Chemicon)] were used at 0.1 mg/ml in Blotto. After incubation with the primary antibody, membranes were washed and incubated with rabbit anti-mouse antibody conjugated to horseradish peroxidase (diluted 1:4000 in Blotto) for 1 h, and protein bands were detected using the enhanced chemiluminescence system (Cell Signaling, Beverly, USA) and quantified by Bio-Rad Quantity One software (Bio-Rad, Hercules, USA).
Western blot analysis
In vitro analysis for cell growth HL-60 and HL-60/A cells (1.0 Â 10 5 cells/well) were seeded in 96-well plates in serum-containing medium and treated with different chemotherapeutics (adriamycin, daunorubicin, and arabinosylcytosine) in different concentrations for 24 h. Cell counting kit-8 (DOJINDO Laboratories, Tokyo, Japan) was used in each well (10 ml/well). After incubation for 4 h at 378C, the coloring reaction was quantified by an automatic plate reader Wellscan MK3 (Labsystem Dragon, Helsinki, Finland) at 450 nm with a reference filter of 650 nm. Growth inhibitory effects were expressed as the 50% inhibitory concentration (IC 50 ) of each drug on cells.
Cells transient nucleofected with SKP2 siRNA and negative control siRNA were resuspended in complete medium, and seeded in 96-well plates (1 Â 10 5 cells/ well). After being incubated for 6 h, the cells were treated with different chemotherapeutics for 24 h, and then used to assess the cell viability using CCK-8 assay.
Flow cytometry
For cell cycle analysis, 1 Â 10 6 cells were stained with propidium iodide. Briefly, different cells (HL-60, HL-60/A, HL-60/A cells transient nucleofected with SKP2 siRNA and negative control siRNA for 24, 48, 72 h, respectively) were washed twice in cold PBS and fixed in ice-cold 70% ethanol overnight. After two more washes in PBS, propidium iodide and RNase A (Sigma, St. Louis, USA) were added to a final concentration of 100 ng/ml each. After incubation for 1 h at room temperature, the cells were analyzed by flow cytometry (FACScan; Becton Dickinson, Temse, Belgium).
Statistical analysis
Results were presented as the mean + standard deviation.
Associations between the variables were tested by Student's t-test. All statistical differences were deemed significant at the level of P , 0.05.
Results
HL-60/A cells had the characteristic of multi-drug resistance with SKP2, MRP high expression and P27 kip1 low expression The drug resistance of HL-60 and HL-60/A cells was summarized in Fig. 1 . According to the result of CCK-8 assay, IC 50 of HL-60 cells to adriamycin, daunorubicin, and arabinosylcytosine were 0.044, 0.035, 0.04 mg/ml, respectively. IC 50 of HL-60/A cells to adriamycin, daunorubicin, and arabinosylcytosine were 2.162, 1.388, and 0.244 mg/ml, respectively. HL-60/A cells were 49.14 fold more resistant to adriamycin and show multidrug resistance phenotype characteristic by 39.20-and 6.43 fold cross-resistance to daunorubicin and arabinosylcytosine, respectively.
RT-PCR and western blot analysis were used to detect the transcription and protein levels of SKP2, P27 kip1 , and MRP, respectively (Figs. 2 and 3) . The transcription level of SKP2 was higher in HL-60/A cells than that in HL-60 cells. SKP2/b-actin ratios in these two different cell lines were 0.83 + 0.03% and 0.52 + 0.01%, respectively. The difference was statistically significant (P , 0.01). The protein level of SKP2 was also higher in HL-60/A cells, and the SKP2/GAPDH ratios were 0.58 + 0.06% and 0.27 + 0.05% (P , 0.01). The transcription and protein levels of MRP in HL-60/A cells were higher than those in HL-60 cells. The MRP/b-actin ratios in HL-60/A and HL-60 cells were 0.61 + 0.07% and 0.34 + 0.12%, , and MRP in HL60 and HL-60/A cells The protein levels of SKP2, P27kip1 and MRP were normalized against GAPDH. The protein levels of MRP in HL60 and HL-60/A were 0.20 + 0.02% and 0.60 + 0.04%, respectively. The difference was significant (t ¼ 2 16.4; P ¼ 0.000). The protein levels of SKP2 in HL60 and HL-60/A were 0.27 + 0.045% and 0.58 + 0.06%, respectively. The difference was significant (t ¼ 2 7.4; P ¼ 0.002). The protein levels of P27 kip1 in HL60 and HL-60/A were 0.63 + 0.13% and 0.30 + 0.13%, respectively. The difference was significant (t ¼ 3.1; P ¼ 0.037). HL-60 cells in the G 0 /G 1 phase were more than in the HL-60/A cells (Fig. 6) . The proportion of S phase and G 2 /M phase in HL-60 cells was 56.04% + 1.12%, the proportion in HL-60/A cells was 64.90% + 0.81%, and the difference was significant (t ¼ 2 11.104, P ¼ 0.001). HL-60/A cells had higher ability of proliferation because cell kinetic analysis could be based on counting of tritiated thymidine labeled S phase cells and mitotic phase (G 2 /M phase) cells.
SKP2 siRNA suppressed the expressions of SKP2 and the subsequent ubiquitin-mediated degradation of p27 kip1 in HL-60/A cells SKP2 siRNA could down-regulate the expression of SKP2 in HL60/A cells. After the cells were nucleofected by siRNA for 24 h, the inhibiting ratios of SKP2 mRNA and SKP2 protein were 43 and 69%, respectively. The effect of siRNA could not last long, because the expression of SKP2 returned to normal when HL-60/A cell line was interfered by siRNA for 72 h. With the down-regulation of SKP2, the expression of P27 kip1 protein was up-regulated by 44% in the first 24 h, but the expression of P27 kip1 mRNA remained the same (Fig. 7) . After 48 and 72 h, P27 kip1 /GAPDH ratios in the cells nucleofected by SKP2 siRNA were 39.0 + 5.6% and 35.0 + 7.6%, respectively. Comparing with ratios to the P27 kip1 protein expression in cells nucleofected by negative control siRNA, the difference was insignificant (Figs. 8 and 9 ). Fig. 10(A,B) ].
SKP2 siRNA improved the chemotherapeutic sensitivity of HL-60/A cells with MRP down-regulation After HL-60/A cells were nucleofected by SKP2 siRNA for 24 h, the IC 50 values of the cells to adriamycin, daunorubicin, and arabinosylcytosine were 2.17, 0.33, and 0.06 mg/ml. In the control groups, the IC 50 values of the cells to adriamycin, daunorubicin, and arabinosylcytosine were 2.49, 1.59, and 0.22 mg/ml, respectively. The cells nucleofected by SKP2 siRNA were more sensitive to adriamycin, daunorubicin, and arabinosylcytosine by 1.15, 4.79 and 3.76 fold, respectively (Fig. 11) .
With the down-regulation of SKP2 expression, the transcription and protein levels of MRP were down-regulated. After the cells were nucleofected by SKP2 siRNA for 24 h, the MRP/b-actin and MRP/GAPDH ratios were 40 + 7% and 29 + 7%, respectively. Comparing with the cells nucleofected by negative control siRNA, the transcription and protein levels of MRP were down-regulated by 55 and 62%, respectively (Figs. 8 and 12 ).
Discussion
Leukemia is one of the most common diseases in hematology. After chemotherapy, about 20% of incipient patients cannot achieve complete remission (CR) [11, 12] . Improving sensitivity of leukemia cells to chemotherapy is crucial for curing leukemia.
SKP2, a kind of oncogenes, relates to cell cycle regulation closely by regulating the expression of P27 kip1 . SKP2 gene locating within 5p13 amplicon encodes the protein of 436 amino acids, containing an F-box, 10 leucine rich repeat (LRR) domain and a C-terminal tail. During the ubiquitin-proteasome pathway, LRR domain directly binds to the substrates, and P27 kip1 is one of the most frequent substrates [13, 14] . P27 kip1 gene is located at 12p13 encoding a protein with a molecular weight of 27 kDa [3] . It is one of the members in CDK-interacting protein/kinase inhibition protein (CIP/KIP) family, inducing G 1 cell cycle arrest [4] . Down-regulation of the negative cell cycle regulators results in cell division [15] . Some researches have demonstrated that the expressions of SKP2 and P27 kip1 were inversely correlated in tumor tissue and both of them were independent prognostic marker of patients. The expression level of P27 kip1 could be one of the useful prognostic molecular markers for AML. Yokozawa et al. [16] . found that patients with high P27 kip1 expression had a significantly increased disease-free survival. The SKP2 overexpression was significantly associated with shorter disease-free survival and overall survival. SKP2 expression was an independent marker for a poor prognosis in AML [17] .
In this study, HL-60/A cells were 49.14 fold more resistant to adriamycin and showed multi-drug resistance phenotype characteristic by 39.20-and 6.43 fold crossresistance to daunorubicin and arabinosylcytosine, respectively. Wada et al. [18] showed that the multi-drug resistance of HL-60/DOX was attributable to the high levels of MRP expression in the HL60/DOX cells, and high expressing MRP induced the alteration of the drug accumulation from enhanced efflux. We used RT-PCR and western blot analysis to detect the MRP expression and found that MRP expression was remarkably increased in HL-60/A cells. High MRP expression might be the reason for the multi-drug resistance of HL-60/A cells.
We found that SKP2 expression in HL-60 cells was lower than that in HL-60/A cells, but the P27 kip1 expression was higher. Results demonstrated that SKP2 and P27 kip1 might be new targets for molecular therapy of tumor. Kataqiri et al. [19] found that SKP2 protein was decreased and the P27 kip1 protein was accumulated in SKP2 siRNA-transfected melanoma cells. SKP2 siRNA inhibited the cell growth of melanoma cells. Agarwal et al. [20] identified SKP2 as a crucial mediator of BCR-ABL-induced leukemogenesis and provided in vivo evidence that SKP2 promoted oncogenesis. Hence stabilization of P27 by inhibiting its recognition by SCF Skp2 may be therapeutically useful. Meanwhile, cell cycles of these two kinds of cells were analyzed by flow cytometry in this study. Results showed that the G 0 /G 1 phase proportion of HL-60/A cells was less than that of HL-60 cells, but the number of HL-60/A cells staying in the S phase and G 2 /M phase were more than that of HL-60 cells. Results showed that drug-resistance leukemia cells had greater ability of proliferation than normal leukemia cells. The results were consistent with the report in which GLC-82 cells were treated with adriamycin at a final concentration of 0.05 mg/ml. Cells in the S phase of the cell cycle were increased. MRP expression was significantly increased in a time-dependent manner, and was positively correlated with changes in the S phase of the cell cycle [21] .
Resent studies demonstrated that SKP2 and P27 kip1 played an important role in the control of tumor cell proliferation, apoptosis, and differentiation, and affected the development of tumor eventually. Fu et al. [22] demonstrated that integrins gave rise to growth inhibition of SMMC-7721 cells through suppressing the proteasomeand calpain-mediated P27 degradation in SMMC-7721 cells. But there are two different views in the relationship between SKP2/P27 kip1 and drug resistance of leukemia cells. Some showed that P27 kip1 inducing G 1 arrested of the cell cycle could make leukemia cells resistant to those cell cycle-dependent chemotherapeutics. Others demonstrated that SKP2 and P27 kip1 played a major role in drug sensitivity of leukemia by detecting bone marrow samples from leukemia patients. Patients with low P27 kip1 had poor prognosis, whereas patients with higher P27 kip1 were more sensitive to chemotherapeutics [23] . Sengupta et al. [24] demonstrated that expression of doubly modified P27 kip1 (T187A, T157A P27 kip1 ) strongly inhibited the growth of imatinib-resistant CML cells, compared with T157A P27 kip1 . The CML growth inhibition is found to be the result of significant G 1 /S arrest with concomitant increase in hypophosphorylated retinoblastoma. Research about other tumors showed the same result. Immunohistochemical results suggested that P27 kip1 might be therapeutically useful as an indicator of response to doxorubicin and/or mitomycin C-based adjuvant chemotherapy for breast cancer [25] . SKP2 might also play a role in cell viability and chemoresistance in non-small cell lung cancers. SKP2 overexpression increased the S phase proportion of the cells and strengthened chemoresistance against camptothecin, cisplatin, and AG1478 in A549 cells [26] . Our study, using RNAi technology to down-regulate the expression of SKP2 and up-regulate the protein expression of P27 kip1 in HL-60/A cells, showed that the G 0 /G 1 phase proportion of HL-60/A cells nucleofected by SKP2 siRNA increased and the proliferation ability of those cells was suppressed. Also, we found that the cells were more SKP2 siRNA inhibits P27 degradation and down-regulates MRP in HL-60/A sensitive to chemotherapeutics (adriamycin, daunorubicin, and arabinosylcytosine) than the controls. The mechanism of multi-drug resistance reversing might be associated with the lowered expression of MRP. SKP2 does not regulate the MRP expression directly because MRP is not a substrate of SKP2. When we downregulated the expression of SKP2, the P27 kip1 expression was up-regulated because the degradation of P27 kip1 protein decreased. P27 kip1 was one of the members in the CIP/KIP family. High expression of P27 made cells arrested in the G 1 phase. Gene transcription and mRNA translation were low in cells that stayed in the G 0 /G 1 phase. So the transcription and protein levels of MRP decreased. MRP was proven to be an efflux pump, altering the drug accumulation by enhancing efflux. When the MRP expression was down-regulated, the drug concentration in cells became higher and the cell became more sensitive to the drug. Maybe there would be other reasons for drug resistance reversion besides the downregulated MRP expression, for example, apoptosis enhancement and cell-cell adhesion damage.
It has been proven that RNAi technology is highly specific and has good effect of gene silencing. Gene therapy will be a new therapeutic tool for oncotherapy. In this study, HL-60/A cells were nucleofected by SKP2 siRNA, which had good effect on SKP2 gene silence. Through exploring the relationship between cell cycle and multi-drug resistance of leukemia cells, we found that cell cycle arresting could reverse the multi-drug resistance of leukemia cells and regulate the expression of MRP, but further experiments were required to explore the mechanism of MRP modulation.
